NCT04407208View on ClinicalTrials.gov

Convalescent Plasma Therapy in Patients With COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

June 22, 2020

Study Completion Date

June 22, 2020

Conditions
ConvalescenceCorona Virus InfectionPlaque
Interventions
BIOLOGICAL

Convalescent plasma

The minimum titer of specific antibody is 1/80

Trial Locations (1)

10410

Gatot Soebroto central army presidential hospital, Jakarta Pusat

Sponsors

Lead Sponsor

Biofarma
All Listed Sponsors
collaborator

Rumah Sakit Pusat Angkatan Darat Gatot Soebroto

OTHER

collaborator

Eijkman Institute for Molecular Biology

OTHER

lead

Biofarma

INDUSTRY

NCT04407208 - Convalescent Plasma Therapy in Patients With COVID-19 | Biotech Hunter | Biotech Hunter